HIGHLIGHTS
- who: Luis del Carpio-Orantes and collaborators from the Study group for the diagnosis and treatment of , in Veracruz, Mexico have published the research work: Comparative analysis between Polymerized Type I Collagen (Fibroquel) and Baricitinib as a potential treatment for moderate-severe COVID-19 in outpatients and inpatients, in the Journal: (JOURNAL) of November/22,/2022
SUMMARY
Since the start of the pandemic, treatments for this entity have evolved. In cases that progress poorly and progress to severity, current drugs are Very few; Tocilizumab, Anakinra, and Baricitinib are treatments authorized by the FDA . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.